Associated Papers
CRISPR/Cas9 Screens Implicate RARA and SPNS1 in Doxorubicin Cardiotoxicity.
McDermott-Roe C et al.
Jacc. Cardiooncology, 2026
Genetic Background in Patients with Cancer Therapy-Induced Cardiomyopathy.
Fazzini L et al.
Journal of Clinical Medicine, 2025
Risk of anthracycline-induced cardiac dysfunction in adolescent and young adult (AYA) cancer survivors: role of genetic susceptibility loci.
Stafford LK et al.
The Pharmacogenomics Journal, 2024
Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs-a proof-of-concept study with doxorubicin.
Pang L et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology, 2024
Harnessing human genetics and stem cells for precision cardiovascular medicine.
Caudal A et al.
Cell Genomics, 2024
Analytical validation of GenoPharm a clinical genotyping open array panel of 46 pharmacogenes inclusive of variants unique to people of African ancestry.
Kanji CR et al.
Plos One, 2023
Pharmacogenetics of Drug Metabolism: The Role of Gene Polymorphism in the Regulation of Doxorubicin Safety and Efficacy.
Bagdasaryan AA et al.
Cancers, 2022
Pharmacogenomics for Prediction of Cardiovascular Toxicity: Landscape of Emerging Data in Breast Cancer Therapies.
Altena R et al.
Cancers, 2022
RARG S427L attenuates the DNA repair response to doxorubicin in induced pluripotent stem cell-derived cardiomyocytes.
Huang H et al.
Stem Cell Reports, 2022
Pharmacogenomic study of anthracycline-induced cardiotoxicity in Mexican pediatric patients.
Vargas-Neri JL et al.
Pharmacogenomics, 2022
RARG variant predictive of doxorubicin-induced cardiotoxicity identifies a cardioprotective therapy.
Magdy T et al.
Cell Stem Cell, 2021
Deciphering pathogenicity of variants of uncertain significance with CRISPR-edited iPSCs.
Guo H et al.
Trends in Genetics : Tig, 2021
Pharmacogenetics of the Central Nervous System-Toxicity and Relapse Affecting the CNS in Pediatric Acute Lymphoblastic Leukemia.
Sági JC et al.
Cancers, 2021
Genome wide association studies for treatment-related adverse effects of pediatric acute lymphoblastic leukemia.
Franca R et al.
Wires Mechanisms of Disease, 2021
Promising genes and variants to reduce chemotherapy adverse effects in acute lymphoblastic leukemia.
Bárcenas-López DA et al.
Translational Oncology, 2021
Genetic factors in anthracycline-induced cardiotoxicity in patients treated for pediatric cancer.
Petrykey K et al.
Expert Opinion on Drug Metabolism & Toxicology, 2020
Variation in RARG increases susceptibility to doxorubicin-induced cardiotoxicity in patient specific induced pluripotent stem cell-derived cardiomyocytes.
Christidi E et al.
Scientific Reports, 2020
Human In Vitro Models for Assessing the Genomic Basis of Chemotherapy-Induced Cardiovascular Toxicity.
Pinheiro EA et al.
Journal of Cardiovascular Translational Research, 2020
Evaluating anthracycline cardiotoxicity associated single nucleotide polymorphisms in a paediatric cohort with early onset cardiomyopathy.
McOwan TN et al.
Cardio-oncology (london, England), 2020
Pediatric Anthracycline-Induced Cardiotoxicity: Mechanisms, Pharmacogenomics, and Pluripotent Stem-Cell Modeling.
Tripaydonis A et al.
Clinical Pharmacology and Therapeutics, 2019
Germline variants in cancer therapy.
Kaehler M et al.
Cancer Drug Resistance (alhambra, Calif.), 2019
Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma.
Sági JC et al.
Bmc Cancer, 2018
Pharmacogenetics of Chemotherapy-Induced Cardiotoxicity.
Chang VY et al.
Current Oncology Reports, 2018
Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trial.
Serie DJ et al.
Pharmacogenetics and Genomics, 2017
Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing?
Magdy T et al.
Pharmacology & Therapeutics, 2016
Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity.
Aminkeng F et al.
British Journal of Clinical Pharmacology, 2016
A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer.
Aminkeng F et al.
Nature Genetics, 2015
Genome-wide analysis to predict protein sequence variations that change phosphorylation sites or their corresponding kinases.
Ryu GM et al.
Nucleic Acids Research, 2009